{"id":"W2617810686","doi":"10.1182/blood-2017-03-771220","title":"A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":122,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Ixazomib; AL amyloidosis; Medicine; Tolerability; Internal medicine; Adverse effect; Nausea; Gastroenterology; Refractory (planetary science); Bortezomib; Amyloidosis; Surgery; Multiple myeloma; Immunology; Carfilzomib; Immunoglobulin light chain; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002104612,0.0002397204,0.0003183147,0.00005148001,0.0001999847,0.00004058375,0.0006197063,0.0001530658,0.00002689713],"category_scores_gemma":[0.0005173876,0.0001579341,0.0001356557,0.00007984267,0.0001353269,0.000009724889,0.0003752655,0.0001508936,0.000006893807],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000243857,"about_ca_system_score_gemma":0.0001209958,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002585146,"about_ca_topic_score_gemma":0.0008302009,"domain_scores_codex":[0.9985262,0.0001536918,0.0003588859,0.0004523188,0.0002279166,0.0002809484],"domain_scores_gemma":[0.9981286,0.00002577351,0.0003720483,0.001343321,0.00005707075,0.0000731876],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0007872269,0.02660161,0.6794851,0.00002774314,0.0004374199,0.00004899791,0.000449062,0.000002560095,0.2884719,0.000005088717,0.001190727,0.002492588],"study_design_scores_gemma":[0.04567537,0.006233681,0.2904906,0.0000870637,0.0003042097,0.00001264619,0.0006315869,0.000004286988,0.6524394,0.00001145892,0.003710436,0.0003991971],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978071,0.0001913392,7.423745e-7,0.0003696,0.0001724965,0.001239857,0.00003678864,0.00001172932,0.0001703103],"genre_scores_gemma":[0.998668,0.00005830711,0.0001077814,0.0001678409,0.0001040898,0.0003832029,0.000009469269,0.00003527724,0.0004660799],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3889945,"threshold_uncertainty_score":0.6440368,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02305316713436628,"score_gpt":0.3148848382474321,"score_spread":0.2918316711130658,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}